The role of cytokines in the pathogenesis of infective endocarditis

• Kolesnikova N.V.
• Samoylenko E.S.

Abstract

In recent years the interest in studying of the cytokines' immunopathogenetic role in the various infectious and inflammatory diseases formation has not weakened. Our review demonstrates the role of cytokines, produced after a direct contact with the antigen. Cytokines cannot be called as factors that relate only to the immune system. They connect the immune, nervous, endocrine, hematopoietic and other systems to engage in the regulation of a general protective reaction. Cytokines play an important role in hematopoietic, tissue homeostasis, intersystem signal transmission. With the development of inflammation, cytokines demonstrate a high spectrum of biological activity and provide maximum efficiency of those body systems that are required at the moment. Infective endocarditis (IE) is a disease of infectious nature with the primary localization of the pathogen on the heart valves and parietal endocardium. IE occurs with the possible generalization of the septic process and the development of immunopatho-logical manifestations. In this regard, the analyze of current information about the pathogenetic role of cytokines in infective endocarditis is the subject of interest in modern research. For the literature review used the databases: eLIBRARY, CyberLeninka, and Medline (Pubmed).

Keywords:infective endocarditis; bacterial endocarditis; diagnosis; pathogenesis; cytokines; review

References

1. Gavrilyuk E.V., Konoplya A.I., Karaulov A.V. The role of immune disorders in the pathogenesis of arterial hypertension. Immunologiya. 2016; 37 (1): 29–35. (in Russian)

2. Polyakov V.P., Nikolaevskiy E.N., Pichko G.A. Non-coronary and infectious heart diseases (modern aspects of the clinic, diagnosis, treatment). Samara, 2010. (in Russian)

3. Vinogradova T.L. Infective and nonbacterial endocarditis: current status issue. Vestnik Rossiyskogo gosudarstvennogo meditsinskogo universiteta. 2010; 6: 8–14. (in Russian)

4. Vinogradova T.L. Infective endocarditis: modern course. Klinitsist. 2011; 3: 4–10. URL: htpps://doi.org/10.17650/1818-8338-2011-3-4-9. (in Russian)

5. Watt G., Lacroix A., Tattevin P., Fournier P.E., Raoult D., Pachirat O., et al. Prospective comparison of infectious endocarditis in Khon Kaen, Thailand and Rennes, France. Am. J. Trop. Med. Hyg. 2015; 92 (4): 871–4. DOI: 10.4269/ajtmh.14-0689.

6. Greenspon A.J., Patel J.D., Lau Е., Ochoa J.A., Frisch D.R., Ho R.T., et al. 16-year trends in infection burden for pacemakers and implantable cardioverter defibrillators in the United States. J. Am. Coll. Cardiol. 2011; 58 (10): 1001–6. DOI: 10.1016/j.jacc.2011.04.033.

7. Federspiel J.J., Stearns S.C., Peppercorn A.F., Chu V.H., Fowler V.G. Increasing US rates of endocarditis with Staphylococcus aureus: 1999–2008. Arch. Intern. Med. 2012; 172 (4): 363–5. DOI: 10.1001/archinternmed.2011.1027.

8. Pericás J.M., Zboromyrska Y., Cervera C., Castañeda X., Almela M., Garcia-de-la-Maria C., et al. Enterococcal endocarditis revisited. Future Microbiol. 2015; 10 (7): 1215–40. DOI: 10.2217/fmb.15.46.

9. Duval X., Delahaye F., Alla F., Tattevin P., Obadia J.F., Moing V.L., et al. Temporal trends in infective endocarditis in the context of Prophylaxis Guideline Modifications. J. Am. Coll. Cardiol. 2012; 59 (22): 1968–76. DOI: 10.1016/j.jacc.2012.02.029.

10. Fournier P.E., Thuny F., Richet H., Lepidi H., Casalta J.P., Arzouni J.P., et al. Comprehensive diagnostic strategy for blood culture-negative endocarditis: a prospective study of 819 new cases. Clin. Infect. Dis. 2010; 51 (2): 131–40. DOI: 10.1086/653675.

11. Ketlinskiy S.A., Simbirtsev A.S. Cytokines. Saint Petersburg: Foliant, 2008. (in Russian).

12. Stagnieva I.V., Simbirtsev A.S. Role of cytokine profile in manifestation of pain in rhinosinusitis. Tsitokiny i vospalenie. 2015; 14 (4): 29–34. DOI: 10.17116/rosrino201725443-47. (in Russian)

13. Schett G., Dayer J.M., Manger B. Interleukin-1 function and role in rheumatic disease. Nat. Rev. Rheumatol. 2016; 12 (1): 14–24. DOI: 10.1038/nrrheum.2016.166.

14. Il’ina A.E., Stanislav M.L., Denisov L.N., Nasonov E.L. Interleukin 1 as an inflammatory mediator and therapeutic target. Nauchno-prakticheskaya revmatologiya. 2011; 49 (5): 62–71. DOI: 10.14412/1995-4484-2011-1463. (in Russian)

15. Dinarello C.A., Van der Meer J.W.M. Treating inflammation by blocking interleukin-1 in humans. Semin. Immunol. 2013; 25 (6): 469–84. DOI: 10.1016/j.smim.2013.10.008.

16. Sims J.E., Smith D.E. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 2010; 10 (2): 89–102. DOI: 10.1038/nri2691.

17. Polevshchikov A.V., Nazarov P.G. Immunology of acute phase proteins of infl ammation and work of R.V. Petrov. Immunologiya. 2020; 41 (2): 167–73. DOI: 10.33029/0206-4952-2020-41-2-167-173. (in Russian)

18. Gabay C., Lamacchia C., Palmer G. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 2010; 6 (4): 232–41. DOI: 10.1038/nrrheum.2010.4.

19. Jimenez-Dalmaroni M.J., Gerswhin M.E., Adamopoulos I.E. The critical role of toll-like receptors – from microbial recognition to autoimmunity: a comprehensive review. Autoimmun. Rev. 2016; 15 (1): 1–8. DOI: 10.1016/j.autrev.2015.08.009.

20. Nasonov E.L., Eliseev M.S. Role of interleukin 1 in the development of human diseases. Nauchno-prakticheskaya revmatologiya. 2016; 54 (1): 60–77. DOI: 10.14412/1995-4484-2016-60-77. (in Russian)

21. Yoshimoto T. The hunt for the source of primary interleukin-4: how we discovered that natural killer T cells and basophils determine T helper type 2 cell differentiation in vivo. Front. Immunol. 2018; 9: 716. DOI: 10.3389/fimmu.2018.00716.

22. Simbirtsev A.S. Cytokines in the pathogenesis of infectious and noninfectious human diseases. Meditsinskiy academicheskiy zhurnal. 2013; 13 (3): 18–41. (in Russian)

23. Sysoev K.A., Chukhlovin A.B., Shakhmanov D.M., Zhdanov K.V., Totolyan A.A. Cytokines and chemokines in the blood plasma of patients with chronic hepatitis C. Infektsia i immunitet. 2013; 3 (1): 49–58. DOI: 10.15789/2220-7619-2013-1-49-58. (in Russian)

24. Frencken J.F., Van Vught L.A., Peelen L.M., Ong D.S.Y., Klein Klouwenberg P.M.C., Horn J., et al. An unbalanced inflammatory cytokine response is not associated with mortality following sepsis: a prospective cohort study. Crit. Care Med. 2017; 45 (5): 493–9. DOI: 10.1097/CCM.0000000000002292.

25. Liang Y., Li X., Zhang X., Li Z., Wang L., Sun Y., et al. Elevated levels of plasma TNF-alpha are associated with microvascular endothelial dysfunction in patients with sepsis through activating the NF-kB and p38 mitogen-activated protein kinase in endothelial cells. Shock. 2014; 41 (4): 275–81. DOI: 10.1097/SHK.0000000000000116.

26. Danilov A.I., Alekseeva I.V., Asner T.V., Vlasova E.E., Drozdovich E.L., Elokhina E.V., et al. Real practice of diagnostics of infectious endocarditis in the Russian Federation: interim results of the MAESTRO study. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2013; 15 (2): 18–9. (in Russian)

27. Nunes M.C.P., Araújo I.R., Carvalho A.T., Andrade L.A., Resende M.H.L., Silva J.L.P., et al. Do cytokines play a role in predicting some features and outcome in infective endocarditis? Adv. Infect. Dis. 2013; 3 (2): 115–9. DOI: 10.4236/aid.2013.32018.

28. Bustamante J., Arévalo A., Tamayo E., Sarria C., Aguilar-Blanco E.M., Heredia M., et al. Cytokine profiles linked to fatal outcome in infective prosthetic valve endocarditis. APMIS. 2013; 122 (6): 526–9. DOI: 10.1111/apm.12189.

29. Yen P., Finley S.D., Engel Stefanini M.O., Popel A.S. A two compartments model of VEGF distribution in the mouse. PLoS One. 2011; 6 (11): e27514. DOI: 10.1371/journal.pone.0027514.

30. Nunes M.C.P., Gelape C.L., Ferrari T.C.A. Profile of infective endocarditis at a tertiary care center in Brazil during a seven-year period: prognostic factors and in-hospital outcome. Int. J. Infect. Dis. 2010; 14 (5): e394–8. DOI: 10.1016/j.ijid.2009.06.024.

31. Josefowicz S.Z., Lu L.F., Rudensky A.Y. Regulatory T cells: mechanisms of differentiation and function. Ann. Rev. Immunol. 2012; 30 (1): 531–64. DOI: 10.1146/annurev.immunol.25.022106.141623.

32. Spaulding A.R., Salgado-Pabón W., Kohler P.L., Horswill A.R., Leung D.Y.M., Schlievert P.M. Staphylococcal and streptococcal superantigen exotoxins. Clin. Microbiol. Rev. 2013; 26 (3): 422–47. DOI: 10.1128/CMR.00104-12.

33. Schulte W., Bernhagen J., Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets – an updated view. Mediators Inflamm. 2013; 2013: 1–16. DOI: 10.1155/2013/165974.

34. Shun C.T., Yeh C.Y., Chang C.J., Wu S.H., Lien H.T., Chen J.Y., et al. Activation of human valve interstitial cells by a viridians streptococci modulin induces chemotaxis of mononuclear cells. J. Infect. Dis. 2009; 199 (10): 1488–96. DOI: 10.1086/598485.

35. Courties G., Moskowitz M.A., Nahrendor M. The innate immune system after ischemic injury: lessons to be learned from the heart and brain. JAMA Neurol. 2014; 71 (2): 233–6. DOI: 10.1001/jamaneurol.2013.5026.

36. Fedorova T.A., Semenenko N.A., Tazina S.Ya., Roytman A.P., Kim T.V., Stefanenko N.I. The markers of inflammation and their diagnostic and prognostic significance under infectious endocarditis. Klinicheskaya meditsina. 2013; 3: 15–8. (in Russian)

37. Markelova E.V., Grachev N.I., Semenikhin A.A., Karaulov A.V. Immunobiochemical predictors of adverse prognosis in patients with acute myocardial infarction after coronary stenting. Rossiyskiy immunologicheskiy zhurnal. 2019; 13 (22): 394–6. (in Russian)

38. Izadi S., Borhani-Hagiga А., Bastani K., Kardeh B., Yadollahi-Khales G., Neydavoodi M. Circulating levels of interleukin-10 and -17 in patients with cerebral sinovenous thrombosis (CSVT) at acute and subacute stages: a prospective case-control study. Iran. J. Immunol. 2018; 15 (3): 221–7. DOI: 10.22034/IJI.2018.39391.

39. Endo S., Suzuki Y., Takahashi G., Shozushima T., Ishikura H., Murai A., et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J. Infect. Chemother. 2012; 18 (6): 891–7. DOI: 10.1007/s10156-012-0435-2.

40. Endo S., Suzuki Y., Takahashi G., Shozushima T., Ishikura H., Murai A., et al. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: a multicenter prospective study. J. Infect. Chemother. 2014; 20 (1): 30–4. DOI: 10.1016/j.jiac.2013.07.005.

41. Moro-Garcia M.A., Echeverria A., Galan-Artimez M.C., Suarez-Garcia F.M., Solano-Jaurrieta J.J., Avanzas-Fernandez P., et al. Immunosenescence and inflammation characterize chronic heart failure patients with more advanced disease. Int. J. Cardiol. 2014; 174 (3): 590–9. DOI: 10.1016/j.ijcard.2014.04.128.

42. Dolgikh S.V., Sysoev K.A., Zhirekhina O.V., Davydenko V.V., Totolyan A.A. Investigation of chemokines and receptors to them in infectious endocarditis. Meditsinskaya immunologiya. 2006; 8 (2–3): 396. (in Russian)

43. Araujo I.R., Ferrari T.C.A., Teixeira-Carvalho A., Campi-Azevedo A.C., Rodrigues L.V., Junior M.H.G., et al. Cytokine signature in infective endocarditis. PLoS One. 2015; 10 (7): e0133631. DOI: 10.1371/journal.pone.0133631.

44. Thuny F., Beurtheret S., Mancini J., Gariboldi V., Casalta J.P., Riberi A., et al. The timing of surgery influences mortality and morbidity in adults with severe complicated infective endocarditis: a propensity analysis. Eur. Heart J. 2011; 32 (16): 2027–33. DOI: 10.1093/eurheartj/ehp089.

45. Baumgartner H., Falk V., Bax J.J., De Bonis M., Hamm C., Holm P.J., et al. Guidelines for the management of valvular heart disease. Eur. Heart J. 2017; 38 (36): 2739–91. DOI: 10.1093/eurheartj/ehx391.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)